ActiveCare+SFT® is a second generation DVT prevention device from Israeli company MCS Medical Compression Systems (DBN) Ltd., that features the firm’s proprietary Synchronized Flow Technology (S.F.T.). The SFT synchronizes the device with the venous phasic flow of respiratory cycle for a supposedly better pumping of blood in lower extremities. The ActiveCare+SFT® been enrolled in the NIH-sponsored study that is evaluating the device’s effectiveness against the enoxaparin low molecular weight heparin (LMWH) therapy in patients undergoing total hip arthroplasty (THA). At the upcoming annual meeting of the American Academy of Orthopaedic Surgeons, Dr. Clifford Colwell Jr from Scripps Clinic in La Jolla will present encouraging preliminary results from the study, that demonstrate the device “to be noninferior to enoxaparin in reducing VTED with decreased bleeding after THA.” The device has not yet been cleared for marketing in Europe or in the US.
More about the technology:
Synchronized Flow Technology (S.F.T.®) is a technology that enables the detection and monitoring of the respiratory related venous phasic flow. Once detected the technology will trigger compression on the vein so that it will be in phase with the venous phasic flow.
Since the venous phasic flow is at its peak when the common femoral vein is open and flow is not disturbed by a descending diaphragm (such as when inhaling) this technology enhances the Peak Venous Velocity (PVV) generated by the device, to levels much higher than the SCD Express, current market leader.
It is well known within the field that the main benefit and clinical attribute of any compression system is the transformation of the sluggish venous flow associated with operative time and the weeks that follow, to a high pulsatile flow. As the amount of blood that is circulating in the legs is determined by the cardiac output and cannot be changed by the use of mechanical systems not synchronized to cardiac rhythm, the only real contribution of mechanical systems is the change of a sluggish flow to a healthy high pulsatile flow.
S.F.T.® technology helps to achieve exactly that objective while still exercising gentle pressure on the leg that does not impair patient tolerance of the treatment and overall compliance. Previous devices needed to exert an intolerable impact on the patients’ leg in an effort to increase PVV through fast inflation of the sleeve, thus impairing the compliance factor that is crucial to the success of the treatment.
Product page: ActiveCare+SFT…
Abstract: Thrombosis Prevention in Total Hip Arthroplasty: CECT vs LMWH…
Flashbacks: ActiveCare DVT®: Goes with Patient; Goes to Cleveland